Efficacy of a Web App for Cognitive Training (MeMo) Regarding Cognitive and Behavioral Performance in People With Neurocognitive Disorders: Randomized Controlled Trial.
Alzheimer disease
apathy
cognition
intervention
motivation
neurocognitive disorders
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
11 03 2020
11 03 2020
Historique:
received:
23
11
2019
accepted:
04
02
2020
revised:
16
01
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Cognitive and behavioral symptoms are the clinical hallmarks of neurocognitive disorders. Cognitive training may be offered to reduce the risks of cognitive decline and dementia and to reduce behavioral symptoms, such as apathy. Information and communication technology approaches, including serious games, can be useful in improving the playful aspect of computerized cognitive training and providing motivating solutions in elderly patients. The objective of this study was to assess the effectiveness of employing the MeMo (Memory Motivation) Web app with regard to cognitive and behavioral symptoms in patients with neurocognitive disorders. MeMo is a Web app that can be used on any Web browser (computer or tablet). The training activities proposed in MeMo are divided into the following two parts: memory and mental flexibility/attention. The study included 46 individuals (mean age 79.4 years) with a diagnosis of neurocognitive disorders at the Institut Claude Pompidou Memory Center in Nice. This randomized controlled study compared the evolution of cognition and behavior between patients not using MeMo (control group) and patients using MeMo (MeMo group) for 12 weeks (four sessions per week). Patients underwent memory and attention tests, as well as an apathy assessment at baseline, week 12 (end of the training period), and week 24 (12 weeks after the end of the training sessions). In addition, to assess the impact of high and low game uses, the MeMo group was divided into patients who used MeMo according to the instructions (about once every 2 days; active MeMo group) and those who used it less (nonactive MeMo group). When comparing cognitive and behavioral scores among baseline, week 12, and week 24, mixed model analysis for each cognitive and behavioral score indicated no significant interaction between testing time and group. On comparing the active MeMo group (n=9) and nonactive MeMo group (n=13), there were significant differences in two attention tests (Trial Making Test A [P=.045] and correct Digit Symbol Substitution Test items [P=.045]) and in the Apathy Inventory (AI) (P=.02). Mixed analysis (time: baseline, week 12, and week 24 × number of active days) indicated only one significant interaction for the AI score (P=.01), with a significant increase in apathy in the nonactive MeMo group. This study indicates that the cognitive and behavioral efficacies of MeMo, a Web-based training app, can be observed only with regular use of the app. Improvements were observed in attention and motivation. ClinicalTrials.gov NCT04142801; https://clinicaltrials.gov/ct2/show/NCT04142801.
Sections du résumé
BACKGROUND
Cognitive and behavioral symptoms are the clinical hallmarks of neurocognitive disorders. Cognitive training may be offered to reduce the risks of cognitive decline and dementia and to reduce behavioral symptoms, such as apathy. Information and communication technology approaches, including serious games, can be useful in improving the playful aspect of computerized cognitive training and providing motivating solutions in elderly patients.
OBJECTIVE
The objective of this study was to assess the effectiveness of employing the MeMo (Memory Motivation) Web app with regard to cognitive and behavioral symptoms in patients with neurocognitive disorders.
METHODS
MeMo is a Web app that can be used on any Web browser (computer or tablet). The training activities proposed in MeMo are divided into the following two parts: memory and mental flexibility/attention. The study included 46 individuals (mean age 79.4 years) with a diagnosis of neurocognitive disorders at the Institut Claude Pompidou Memory Center in Nice. This randomized controlled study compared the evolution of cognition and behavior between patients not using MeMo (control group) and patients using MeMo (MeMo group) for 12 weeks (four sessions per week). Patients underwent memory and attention tests, as well as an apathy assessment at baseline, week 12 (end of the training period), and week 24 (12 weeks after the end of the training sessions). In addition, to assess the impact of high and low game uses, the MeMo group was divided into patients who used MeMo according to the instructions (about once every 2 days; active MeMo group) and those who used it less (nonactive MeMo group).
RESULTS
When comparing cognitive and behavioral scores among baseline, week 12, and week 24, mixed model analysis for each cognitive and behavioral score indicated no significant interaction between testing time and group. On comparing the active MeMo group (n=9) and nonactive MeMo group (n=13), there were significant differences in two attention tests (Trial Making Test A [P=.045] and correct Digit Symbol Substitution Test items [P=.045]) and in the Apathy Inventory (AI) (P=.02). Mixed analysis (time: baseline, week 12, and week 24 × number of active days) indicated only one significant interaction for the AI score (P=.01), with a significant increase in apathy in the nonactive MeMo group.
CONCLUSIONS
This study indicates that the cognitive and behavioral efficacies of MeMo, a Web-based training app, can be observed only with regular use of the app. Improvements were observed in attention and motivation.
TRIAL REGISTRATION
ClinicalTrials.gov NCT04142801; https://clinicaltrials.gov/ct2/show/NCT04142801.
Identifiants
pubmed: 32159519
pii: v22i3e17167
doi: 10.2196/17167
pmc: PMC7097721
doi:
Banques de données
ClinicalTrials.gov
['NCT04142801']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e17167Informations de copyright
©Philippe Robert, Valeria Manera, Alexandre Derreumaux, Marion Ferrandez Y Montesino, Elsa Leone, Roxane Fabre, Jeremy Bourgeois. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 11.03.2020.
Références
Front Aging Neurosci. 2015 Mar 17;7:24
pubmed: 25852542
BMJ Open. 2019 Jun 19;9(6):e024982
pubmed: 31221867
Cereb Cortex. 2006 Jul;16(7):916-28
pubmed: 16207933
Ann Intern Med. 2018 Jan 2;168(1):63-68
pubmed: 29255842
Am J Psychiatry. 2017 Apr 1;174(4):329-340
pubmed: 27838936
Psychol Aging. 2008 Dec;23(4):765-77
pubmed: 19140648
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
BMC Geriatr. 2018 Sep 15;18(1):213
pubmed: 30219036
Front Aging Neurosci. 2018 Feb 02;10:13
pubmed: 29456501
Eur Psychiatry. 2018 Oct;54:71-76
pubmed: 30125783
Neurology. 1994 Dec;44(12):2308-14
pubmed: 7991117
JAMA Psychiatry. 2018 Oct 1;75(10):1012-1021
pubmed: 30027214
Alzheimers Dement (Amst). 2015 Mar 29;1(1):112-24
pubmed: 27239498
Am J Geriatr Psychiatry. 2019 Aug;27(8):873-882
pubmed: 30910421
Gerontologist. 2019 Nov 16;59(6):e764-e781
pubmed: 30605502
Int J Geriatr Psychiatry. 2019 Oct;34(10):1369-1377
pubmed: 30993719
Nat Rev Neurosci. 2018 Aug;19(8):470-484
pubmed: 29946157
Psychol Med. 1989 Nov;19(4):1015-22
pubmed: 2594878
J Alzheimers Dis. 2016 Jun 30;53(4):1299-314
pubmed: 27372645
Front Psychol. 2017 Jul 25;8:1243
pubmed: 28790945
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Int J Geriatr Psychiatry. 2002 Dec;17(12):1099-105
pubmed: 12461757
Lancet. 2015 Jun 6;385(9984):2255-63
pubmed: 25771249
Int J Geriatr Psychiatry. 2019 Sep;34(9):1326-1334
pubmed: 30198597
J Neurol Sci. 2011 Nov 15;310(1-2):58-60
pubmed: 21831400
Front Aging Neurosci. 2014 Mar 24;6:54
pubmed: 24715864
Am J Geriatr Psychiatry. 2020 Apr;28(4):410-420
pubmed: 31495772
J Prev Alzheimers Dis. 2020;7(1):29-36
pubmed: 32010923
Neuropsychiatr Dis Treat. 2015 Mar 03;11:557-63
pubmed: 25834437
Neurobiol Aging. 2000 Nov-Dec;21(6):845-61
pubmed: 11124429
Neuron. 2016 Apr 20;90(2):214-8
pubmed: 27100194
J Med Internet Res. 2013 Dec 03;15(12):e270
pubmed: 24300212
Clin Interv Aging. 2013;8:623-33
pubmed: 23766638
Neurology. 1988 Jun;38(6):900-3
pubmed: 3368071
Am J Geriatr Psychiatry. 2013 Jul;21(7):655-63
pubmed: 23602310